Rems as anti competitive barrier how celgene's steps used mandatory patient registry to deny generic rld samples?

Q: Rems as anti competitive barrier how celgene's steps used mandatory patient registry to deny generic rld samples?

TL;DR Celgene put a Risk Evaluation and Mitigation Strategy (REMS) on its drug (for example, Jakafi® —ruxolitinib). The REMS required a mandatory patient‑registry that only the brand‑name manufacturer could run. Because the generic developer needed a Reference Listed Drug (RLD) sample to test its product, Celgene used the registry as a gatekeeper: it would only provide the sample if the generic company first enrolled patients in the registry (or if Celgene agreed to share data). The result was that the generic was effectively blocked from getting the RLD sample and, by extension, from launching its own product for months—an anti‑competitive barrier that the FTC and the FDA have scrutinized. 1. What is a REMS and why do brands use them? Item Explanation REMS A federal safety‑management program designed to ensure that the benefits of a drug outweigh its risks. Typical elements 1. Patient registry 2. Labeling 3. Medication guide 4. Physician training 5. Restricted distribution When FDA requires it Serious safety concerns (e.g., rare infections, birth defects, organ toxicity). Who decides The brand‑name sponsor (Celgene), in consultation with the FDA. In

Question

Accepted Answer

TL;DR
Celgene put a Risk Evaluation and Mitigation Strategy (REMS) on its drug (for example, Jakafi®—ruxolitinib).
The REMS required a mandatory patient‑registry that only the brand‑name manufacturer could run.
Because the generic developer needed a Reference Listed Drug (RLD) sample to test its product, Celgene used the registry as a gatekeeper: it would only provide the sample if the generic company first enrolled patients in the registry (or if Celgene agreed to share data). The result was that the generic was effectively blocked from getting the RLD sample and, by extension, from launching its own product for months—an anti‑competitive barrier that the FTC and the FDA have scrutinized.

1. What is a REMS and why do brands use them?

Item	Explanation
REMS	A federal safety‑management program designed to ensure that the benefits of a drug outweigh its risks.
Typical elements	1. Patient registry 2. Labeling 3. Medication guide 4. Physician training 5. Restricted distribution
When FDA requires it	Serious safety concerns (e.g., rare infections, birth defects, organ toxicity).
Who decides	The brand‑name sponsor (Celgene), in consultation with the FDA.

In

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Rems as anti competitive barrier how celgene's steps used mandatory patient registry to deny generic rld samples?

1. What is a REMS and why do brands use them?